Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q16342

UPID:
PDCD2_HUMAN

ALTERNATIVE NAMES:
Zinc finger MYND domain-containing protein 7; Zinc finger protein Rp-8

ALTERNATIVE UPACC:
Q16342; E9PCU7; F5GYS7; Q58HM9; Q58HN0; Q9UH12

BACKGROUND:
The Programmed cell death protein 2, with alternative names Zinc finger MYND domain-containing protein 7 and Zinc finger protein Rp-8, is believed to have a regulatory function. It may significantly influence cell death and cell proliferation, indicating its critical role in cellular regulation and homeostasis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Programmed cell death protein 2 could lead to groundbreaking therapeutic approaches. Given its crucial role in regulating cell death and proliferation, targeting this protein could offer new avenues for the development of treatments for diseases characterized by abnormal cell growth and death.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.